6 April 2023
Futura Medical plc
("Futura" or the "Company")
Directors' / PDMR Dealing and Grant of Options
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announces that it has today, granted options over a total of 1,934,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 858,000 options were granted to Directors and PDMRs as detailed below. The options are part of annual awards made by Futura in accordance with existing share schemes.
| Director | Number | Exercise | Exercise period | Total number | Total number |
| | | | | | |
| J H Barder | 330,000 | 43.60p | 1 April 2026 - 31 Mar 2033 | 2,415,716 | 1,440,972 |
| | | | | | |
| A Hildreth | 264,000 | 43.60p | 1 April 2026 - 31 Mar 2033 | 1,772,340 | 142,857 |
| | | | | | |
| K W James | 264,000 | 43.60p | 1 April 2026 - 31 Mar 2033 | 1,945,227 | 299,581 |
Of the total 1,934,000 options, 1,046,000 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 888,000 were granted under the unapproved scheme.
Vesting is subject to the achievement of a performance-related milestone and that the Director/PDMR/employee remains employed with the Company as at the date of exercise. Further disclosures are contained in the tables below.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has previously conducted an initial Phase 3 study using MED3000 in ED, referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A second confirmatory Phase 3 clinical study, "FM71" was also conducted to support Futura's regulatory submission to the FDA with 96 ED patients and endpoints at 24 weeks, demonstrating that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for OTC classification.
Eroxon® is CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | James Barder | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Futura Medical plc | ||||
| b) | LEI | 21380053QLT46UNV2303 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
| b) | Nature of the transaction | Grant of options over Ordinary Shares
| ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
| e) | Date of the transaction | 6 April 2023 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Angela Hildreth | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Finance Director and | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Futura Medical plc | ||||
| b) | LEI | 21380053QLT46UNV2303 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
| b) | Nature of the transaction | Grant of options over Ordinary Shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
| e) | Date of the transaction | 6 April 2023 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Ken James | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Director | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Futura Medical plc | ||||
| b) | LEI | 21380053QLT46UNV2303 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
| b) | Nature of the transaction | Grant of options over Ordinary Shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
| e) | Date of the transaction | 6 April 2023 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.